Drug utilization reviews
•Download as PPT, PDF•
20 likes•3,796 views
This document discusses drug utilization reviews (DUR), also known as drug utilization evaluations (DUE) or medication utilization evaluations (MUE). DURs involve comprehensive review of patient prescription and medication data before, during, and after dispensing to ensure appropriate medication decisions and positive outcomes. DURs aim to promote optimal medication therapy, prevent medication-related problems, evaluate medication effectiveness, improve patient safety, and stimulate improvements in medication use processes. The document also outlines the value of DUR programs in helping health systems understand and improve prescribing, administration, and medication use.
Report
Share
Report
Share
Recommended
Drug Utilization review
Here is the method discussed on how to calculate medication utilization also known as drug utilization evaluation .
Prescription event monitoring
The document describes Prescription Event Monitoring (PEM), a method of pharmacovigilance that involves collecting information on patient outcomes after being prescribed new medications. PEM was developed in the 1980s in the UK to address limitations of spontaneous adverse event reporting. It involves sending questionnaires to prescribers to obtain follow-up data on patients. Analysis of the data provides incidence rates of adverse events and allows detection of potential safety issues with new drugs. Modified PEM (M-PEM) expands the method to collect additional targeted safety information.
Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)
This document discusses drug use evaluation (DUE), medication use evaluation (MUE), and drug utilization review (DUR). DUE and MUE involve ongoing, criteria-based evaluation of drug use at the individual patient level to ensure appropriate medication use and improve outcomes. DUR also reviews medication use against criteria and can occur prospectively, concurrently, or retrospectively. The goals of these programs are to promote optimal medication therapy, ensure standards of care are met, and prevent medication-related problems through ongoing review and collaboration between healthcare providers.
DRUG USE MEASURES.pptx
Different outcome measures in Pharmacoepidemiology includes monetary units, no. of prescriptions, DDDs, PDD, etc.
Developing therapeutic guidelines
This document discusses the development of therapeutic guidelines. It defines therapeutic guidelines as clinical practice guidelines written for prescribers to provide treatment recommendations based on current evidence. The document outlines the need for guidelines to improve patient care quality and consistency while controlling healthcare costs. It describes the composition of guideline development groups and the multi-step process involved, including identifying the problem and literature, obtaining expert opinions, reviewing evidence, and disseminating the completed guidelines. Potential limitations of guidelines like complexity and physician acceptance are also discussed.
Detection, reporting and management of adverse events
This document discusses adverse drug reactions (ADRs), including definitions, classifications, detection, reporting, and management. It notes that ADRs are a major clinical problem that can cause suffering and increased healthcare costs. It emphasizes the importance of monitoring and reporting ADRs to improve patient safety. Pharmacists can play an important role by monitoring high-risk patients and drugs, educating on ADR reporting, and assisting in the detection and assessment of ADRs. Timely reporting of ADRs is crucial to help prevent human suffering and unnecessary costs from drug-related injuries.
Defined daily dose-DDD
Defined daily dose-DDD
B Pharm, Pharm D and medicine syllabus
Useful for examination and regulatory function information
Useful for Pharmacovigilance interview and medical coding also.
Good Luck and all the best!!!
Overview regulatory environment in usa,europe,india
The document summarizes the process for clinical research and drug approval by the FDA. It describes the multi-step process including pre-clinical research in animals, Phase 1-3 clinical trials in humans to test safety and efficacy, and the submission of a New Drug Application. The FDA rigorously reviews data at each stage before approving progression to the next stage to ensure safety. The overall process aims to establish that new drugs are safe and effective for use by the American public.
Recommended
Drug Utilization review
Here is the method discussed on how to calculate medication utilization also known as drug utilization evaluation .
Prescription event monitoring
The document describes Prescription Event Monitoring (PEM), a method of pharmacovigilance that involves collecting information on patient outcomes after being prescribed new medications. PEM was developed in the 1980s in the UK to address limitations of spontaneous adverse event reporting. It involves sending questionnaires to prescribers to obtain follow-up data on patients. Analysis of the data provides incidence rates of adverse events and allows detection of potential safety issues with new drugs. Modified PEM (M-PEM) expands the method to collect additional targeted safety information.
Drug Use Evaluation & Drug Utilisation Review (DUE & DUR)
This document discusses drug use evaluation (DUE), medication use evaluation (MUE), and drug utilization review (DUR). DUE and MUE involve ongoing, criteria-based evaluation of drug use at the individual patient level to ensure appropriate medication use and improve outcomes. DUR also reviews medication use against criteria and can occur prospectively, concurrently, or retrospectively. The goals of these programs are to promote optimal medication therapy, ensure standards of care are met, and prevent medication-related problems through ongoing review and collaboration between healthcare providers.
DRUG USE MEASURES.pptx
Different outcome measures in Pharmacoepidemiology includes monetary units, no. of prescriptions, DDDs, PDD, etc.
Developing therapeutic guidelines
This document discusses the development of therapeutic guidelines. It defines therapeutic guidelines as clinical practice guidelines written for prescribers to provide treatment recommendations based on current evidence. The document outlines the need for guidelines to improve patient care quality and consistency while controlling healthcare costs. It describes the composition of guideline development groups and the multi-step process involved, including identifying the problem and literature, obtaining expert opinions, reviewing evidence, and disseminating the completed guidelines. Potential limitations of guidelines like complexity and physician acceptance are also discussed.
Detection, reporting and management of adverse events
This document discusses adverse drug reactions (ADRs), including definitions, classifications, detection, reporting, and management. It notes that ADRs are a major clinical problem that can cause suffering and increased healthcare costs. It emphasizes the importance of monitoring and reporting ADRs to improve patient safety. Pharmacists can play an important role by monitoring high-risk patients and drugs, educating on ADR reporting, and assisting in the detection and assessment of ADRs. Timely reporting of ADRs is crucial to help prevent human suffering and unnecessary costs from drug-related injuries.
Defined daily dose-DDD
Defined daily dose-DDD
B Pharm, Pharm D and medicine syllabus
Useful for examination and regulatory function information
Useful for Pharmacovigilance interview and medical coding also.
Good Luck and all the best!!!
Overview regulatory environment in usa,europe,india
The document summarizes the process for clinical research and drug approval by the FDA. It describes the multi-step process including pre-clinical research in animals, Phase 1-3 clinical trials in humans to test safety and efficacy, and the submission of a New Drug Application. The FDA rigorously reviews data at each stage before approving progression to the next stage to ensure safety. The overall process aims to establish that new drugs are safe and effective for use by the American public.
The regulation of complementary medicines
The Therapeutic Goods Administration (TGA) regulates complementary medicines in Australia using a risk-based, two-tiered system. Lower risk listed medicines can be marketed with minimal pre-market evaluation, while higher risk registered medicines require pre-market assessment of quality, safety and efficacy. The TGA oversees post-market monitoring and compliance reviews to ensure that medicines meet regulatory requirements. Guidance materials provide information on evidence requirements and the different pathways for listed and registered complementary medicines.
Pharmacovigilance and role of pharmacist
Reporting of ADRs, Management of, Definition, aim, and scope of Pharmacovigilance, Role of pharmacist in pharmacovigilance
Unit 1 pharmacoepidemiology
Pharmacoepidemiology is the study of the use and effects of drugs in large populations. The document discusses the definition, origins, need and applications of pharmacoepidemiology. Specifically, it notes that pharmacoepidemiology applies epidemiological techniques to study drug use and effects in populations. It also discusses limitations of pre-marketing drug trials that pharmacoepidemiology aims to address through post-marketing surveillance and other techniques.
Meta analysis and spontaneous reporting
This document discusses meta-analysis, which is a statistical technique for combining the results of multiple independent studies on a topic to obtain an overall estimate of treatment effect. It defines meta-analysis and outlines its key functions and steps, including performing a literature search, establishing inclusion/exclusion criteria, collecting and analyzing data, and formulating conclusions. The document also compares fixed and random effect models of meta-analysis and discusses guidelines and software used in conducting meta-analyses.
Pharmacy Practice: Managing Formularies
This document discusses principles of managing a formulary system in a healthcare institution. It defines key terms like formulary, formulary system management, and discusses the purpose and objectives of formulary management. It describes the roles of the pharmacy and therapeutics committee and drug review panels in the formulary management process. The document outlines principles for drug selection and formulary maintenance, including considering clinical effectiveness, safety and cost when adding or removing drugs from the formulary.
Concept f risk
1. Pharmacoepidemiology determines the relationship between drug exposure and disease frequency in a population. It estimates risk but does not prove causation for individuals.
2. Risk is the probability of harm from a risk factor, like a drug. It is relative and uncertain, depending on factors like genetics, environment, and their interactions over time.
3. Epidemiological studies measure risk using measures like relative risk, odds ratio, and attributable risk to quantify relationships between exposure and disease while accounting for biases and confounding variables.
DRUG UTILIZATION EVALUATION
Drug use evaluation (DUE) is a quality improvement process that reviews prescribing patterns to promote appropriate drug use. It involves identifying a drug or therapeutic area, developing criteria and standards, collecting data, evaluating results, providing feedback, and implementing interventions. The process then reevaluates drug use and revises the DUE program as needed. The presented document outlines the 11 steps of a DUE process focusing on monitoring renal function during aminoglycoside therapy.
14ab1 t0004 therapeutic guidelines
The document outlines guidelines for developing hospital formularies and therapeutic guidelines. It states that a pharmacy and therapeutics committee composed of physicians and pharmacists should be appointed to prepare the hospital formulary system. The committee will develop policies and procedures governing drug selection, procurement, storage, distribution, and use. Therapeutic guidelines are developed by independent organizations to provide evidence-based recommendations for treating common medical conditions through comparative disease guidelines. The guidelines are clinically oriented, cover common treatment areas, and provide authorized interpretations of evidence from medical experts. An example therapeutic guideline for treating acute cystitis is provided.
Studies of vaccine safety (Pharmacoepidemiology) V PharmD
This document discusses selected special applications of pharmacoepidemiology, focusing on studies of vaccine safety. It describes various methods used to monitor vaccine safety, including pre-licensure clinical trials, post-licensure surveillance systems like VAERS, and epidemiological studies. It addresses some methodological challenges in vaccine safety studies like assessing causality, accounting for confounding factors, and identifying rare adverse events. Large automated databases like the Vaccine Safety Datalink are highlighted as a valuable tool for monitoring vaccine safety on a population-level.
HOME MEDICATION REVIEW FOR PHARM D STUDENTS.ppt
hOME MEDICATION REVIEW IS out standing self-employment opportunities with good clinical skills and hand on practice for pharm d students..its well an established program in Australia.
Adverse drug reaction monitoring and reporting
This document discusses types of adverse drug reactions and factors influencing them. It describes types A-E reactions, which include augmented, bizarre, chemical, delayed and end of treatment reactions. Polypharmacy, age, drug characteristics, gender, race and genetic factors can influence susceptibility. Detection methods include pre-marketing studies, post-marketing surveillance, underreporting and communicating reactions. Healthcare professionals should monitor high-risk patients and gather information to assess causality between drugs and adverse events. Underreporting is common due to various barriers but can be addressed through improved reporting systems and education.
Rational drug use
The document discusses rational use of medicines and the role of pharmacists in promoting rational use. It defines rational use of medicines according to WHO as ensuring patients receive appropriate medicines based on their clinical needs at the lowest cost. Pharmacists can promote rational use by properly managing drug stocks, dispensing medications correctly with patient education, and participating in pharmacovigilance programs. The document also outlines several other strategies to improve rational use, including developing treatment guidelines, regulating drug promotion, and educating both healthcare providers and the public.
Education and training program in the hospital.
Includes information about Education and training programs planned in hospital by hospital pharmacy. Useful for B Pharmacy 4th year student, and for M pharmacy (clinical pharmacy) student.
Clinical Pharmacy
Introduction to clinical pharmacy, Concept and Objectives of clinical pharmacy, Function and responsibilities of clinical pharmacist, Clinical Pharmacy services.
Pharmacovigilance methods
Active Surveillance, Passive Surveillance, Comparative observational methods, stimulated reporting, targeted clinical investigations
Ward round participation
Definition of the ward round
Clinical Pharmacist in ward round
Ward round in Indian Scenario
Types of Ward round
Legal requirements
This document outlines various legal requirements for starting a community pharmacy in India. It discusses the minimum area required, rent agreements, refrigeration requirements, and that an in-charge qualified pharmacist is necessary. It also summarizes legal aspects of contracts, payment terms regarding time, place and mode of payment. Pricing considerations for bulk drugs and drug formulations are defined by law. Various license forms are specified according to the category of drugs to be sold and qualified person requirements.
Clinical pharmacy services
The document discusses clinical pharmacy services provided at hospitals. It focuses on ward round participation, drug therapy review, and pharmacist interventions. Key services discussed include participating in ward rounds to optimize patient treatment, monitoring drug therapy through activities like therapeutic drug monitoring and medication order review, endorsing medication charts to prevent errors, and performing clinical reviews to evaluate treatment response and safety. The pharmacist plays an important role as part of the clinical team in these activities to enhance patient outcomes.
post marketing –surveillance methods
Post-marketing surveillance is important to identify adverse drug reactions that were not detected in pre-market clinical trials due to limited sample sizes. There are several methods used for post-marketing surveillance including spontaneous reporting, cohort studies, and case-control studies. These methods help monitor drug safety once a drug is on the market and exposed to a more diverse population and conditions compared to clinical trials. Post-marketing surveillance is especially important for detecting rare or long-term adverse effects.
Prescription Event Monitoring & Record Linkage Systems
- Prescription-Event Monitoring (PEM) is a non-interventional observational cohort technique used to study the safety of new medications prescribed by general practitioners. It involves collecting data on all clinical events reported by patients after being prescribed a new drug.
- PEM provides clinically useful safety information as it establishes incidence densities for all reported events during treatment with the monitored drug based on data collected from the first 5,000-18,000 prescriptions. This allows for comparisons of event rates before and after drug use.
- While PEM provides nationally representative data on new drugs in real-world settings, it also has disadvantages like an inability to measure compliance or determine use of non-prescription medications.
A PROSPECTIVE STUDY OF DRUG UTILIZATION PATTERN AND EVALUATION USING WHO GUI...
This document describes a prospective study conducted to evaluate drug utilization patterns and prescribing practices in a government hospital in India using WHO prescribing indicators. Data was collected from 282 patient records over 6 months across various wards. The study aimed to promote rational drug use, avoid polypharmacy, prevent antibiotic resistance, and estimate disease prevalence. Key metrics analyzed included the average number of drugs per prescription, percentage of generics prescribed, consultation times, and drug availability. The findings could provide insights into prescribing quality and opportunities for improvement.
Drug utilization review 1
This document discusses drug utilization review (DUR), which is a systematic process to ensure appropriate medication use. DUR involves reviewing patient medication and health histories before, during, and after dispensing. It can help prevent unnecessary drug use, adverse reactions, and improve effectiveness. The document outlines the classification, goals, and steps to establish a basic hospital DUR program, including forming a committee, developing policies/procedures, identifying drugs for review, establishing criteria, collecting/evaluating data, implementing interventions if needed, and re-evaluating the program annually.
More Related Content
What's hot
The regulation of complementary medicines
The Therapeutic Goods Administration (TGA) regulates complementary medicines in Australia using a risk-based, two-tiered system. Lower risk listed medicines can be marketed with minimal pre-market evaluation, while higher risk registered medicines require pre-market assessment of quality, safety and efficacy. The TGA oversees post-market monitoring and compliance reviews to ensure that medicines meet regulatory requirements. Guidance materials provide information on evidence requirements and the different pathways for listed and registered complementary medicines.
Pharmacovigilance and role of pharmacist
Reporting of ADRs, Management of, Definition, aim, and scope of Pharmacovigilance, Role of pharmacist in pharmacovigilance
Unit 1 pharmacoepidemiology
Pharmacoepidemiology is the study of the use and effects of drugs in large populations. The document discusses the definition, origins, need and applications of pharmacoepidemiology. Specifically, it notes that pharmacoepidemiology applies epidemiological techniques to study drug use and effects in populations. It also discusses limitations of pre-marketing drug trials that pharmacoepidemiology aims to address through post-marketing surveillance and other techniques.
Meta analysis and spontaneous reporting
This document discusses meta-analysis, which is a statistical technique for combining the results of multiple independent studies on a topic to obtain an overall estimate of treatment effect. It defines meta-analysis and outlines its key functions and steps, including performing a literature search, establishing inclusion/exclusion criteria, collecting and analyzing data, and formulating conclusions. The document also compares fixed and random effect models of meta-analysis and discusses guidelines and software used in conducting meta-analyses.
Pharmacy Practice: Managing Formularies
This document discusses principles of managing a formulary system in a healthcare institution. It defines key terms like formulary, formulary system management, and discusses the purpose and objectives of formulary management. It describes the roles of the pharmacy and therapeutics committee and drug review panels in the formulary management process. The document outlines principles for drug selection and formulary maintenance, including considering clinical effectiveness, safety and cost when adding or removing drugs from the formulary.
Concept f risk
1. Pharmacoepidemiology determines the relationship between drug exposure and disease frequency in a population. It estimates risk but does not prove causation for individuals.
2. Risk is the probability of harm from a risk factor, like a drug. It is relative and uncertain, depending on factors like genetics, environment, and their interactions over time.
3. Epidemiological studies measure risk using measures like relative risk, odds ratio, and attributable risk to quantify relationships between exposure and disease while accounting for biases and confounding variables.
DRUG UTILIZATION EVALUATION
Drug use evaluation (DUE) is a quality improvement process that reviews prescribing patterns to promote appropriate drug use. It involves identifying a drug or therapeutic area, developing criteria and standards, collecting data, evaluating results, providing feedback, and implementing interventions. The process then reevaluates drug use and revises the DUE program as needed. The presented document outlines the 11 steps of a DUE process focusing on monitoring renal function during aminoglycoside therapy.
14ab1 t0004 therapeutic guidelines
The document outlines guidelines for developing hospital formularies and therapeutic guidelines. It states that a pharmacy and therapeutics committee composed of physicians and pharmacists should be appointed to prepare the hospital formulary system. The committee will develop policies and procedures governing drug selection, procurement, storage, distribution, and use. Therapeutic guidelines are developed by independent organizations to provide evidence-based recommendations for treating common medical conditions through comparative disease guidelines. The guidelines are clinically oriented, cover common treatment areas, and provide authorized interpretations of evidence from medical experts. An example therapeutic guideline for treating acute cystitis is provided.
Studies of vaccine safety (Pharmacoepidemiology) V PharmD
This document discusses selected special applications of pharmacoepidemiology, focusing on studies of vaccine safety. It describes various methods used to monitor vaccine safety, including pre-licensure clinical trials, post-licensure surveillance systems like VAERS, and epidemiological studies. It addresses some methodological challenges in vaccine safety studies like assessing causality, accounting for confounding factors, and identifying rare adverse events. Large automated databases like the Vaccine Safety Datalink are highlighted as a valuable tool for monitoring vaccine safety on a population-level.
HOME MEDICATION REVIEW FOR PHARM D STUDENTS.ppt
hOME MEDICATION REVIEW IS out standing self-employment opportunities with good clinical skills and hand on practice for pharm d students..its well an established program in Australia.
Adverse drug reaction monitoring and reporting
This document discusses types of adverse drug reactions and factors influencing them. It describes types A-E reactions, which include augmented, bizarre, chemical, delayed and end of treatment reactions. Polypharmacy, age, drug characteristics, gender, race and genetic factors can influence susceptibility. Detection methods include pre-marketing studies, post-marketing surveillance, underreporting and communicating reactions. Healthcare professionals should monitor high-risk patients and gather information to assess causality between drugs and adverse events. Underreporting is common due to various barriers but can be addressed through improved reporting systems and education.
Rational drug use
The document discusses rational use of medicines and the role of pharmacists in promoting rational use. It defines rational use of medicines according to WHO as ensuring patients receive appropriate medicines based on their clinical needs at the lowest cost. Pharmacists can promote rational use by properly managing drug stocks, dispensing medications correctly with patient education, and participating in pharmacovigilance programs. The document also outlines several other strategies to improve rational use, including developing treatment guidelines, regulating drug promotion, and educating both healthcare providers and the public.
Education and training program in the hospital.
Includes information about Education and training programs planned in hospital by hospital pharmacy. Useful for B Pharmacy 4th year student, and for M pharmacy (clinical pharmacy) student.
Clinical Pharmacy
Introduction to clinical pharmacy, Concept and Objectives of clinical pharmacy, Function and responsibilities of clinical pharmacist, Clinical Pharmacy services.
Pharmacovigilance methods
Active Surveillance, Passive Surveillance, Comparative observational methods, stimulated reporting, targeted clinical investigations
Ward round participation
Definition of the ward round
Clinical Pharmacist in ward round
Ward round in Indian Scenario
Types of Ward round
Legal requirements
This document outlines various legal requirements for starting a community pharmacy in India. It discusses the minimum area required, rent agreements, refrigeration requirements, and that an in-charge qualified pharmacist is necessary. It also summarizes legal aspects of contracts, payment terms regarding time, place and mode of payment. Pricing considerations for bulk drugs and drug formulations are defined by law. Various license forms are specified according to the category of drugs to be sold and qualified person requirements.
Clinical pharmacy services
The document discusses clinical pharmacy services provided at hospitals. It focuses on ward round participation, drug therapy review, and pharmacist interventions. Key services discussed include participating in ward rounds to optimize patient treatment, monitoring drug therapy through activities like therapeutic drug monitoring and medication order review, endorsing medication charts to prevent errors, and performing clinical reviews to evaluate treatment response and safety. The pharmacist plays an important role as part of the clinical team in these activities to enhance patient outcomes.
post marketing –surveillance methods
Post-marketing surveillance is important to identify adverse drug reactions that were not detected in pre-market clinical trials due to limited sample sizes. There are several methods used for post-marketing surveillance including spontaneous reporting, cohort studies, and case-control studies. These methods help monitor drug safety once a drug is on the market and exposed to a more diverse population and conditions compared to clinical trials. Post-marketing surveillance is especially important for detecting rare or long-term adverse effects.
Prescription Event Monitoring & Record Linkage Systems
- Prescription-Event Monitoring (PEM) is a non-interventional observational cohort technique used to study the safety of new medications prescribed by general practitioners. It involves collecting data on all clinical events reported by patients after being prescribed a new drug.
- PEM provides clinically useful safety information as it establishes incidence densities for all reported events during treatment with the monitored drug based on data collected from the first 5,000-18,000 prescriptions. This allows for comparisons of event rates before and after drug use.
- While PEM provides nationally representative data on new drugs in real-world settings, it also has disadvantages like an inability to measure compliance or determine use of non-prescription medications.
What's hot (20)
Studies of vaccine safety (Pharmacoepidemiology) V PharmD
Studies of vaccine safety (Pharmacoepidemiology) V PharmD
Prescription Event Monitoring & Record Linkage Systems
Prescription Event Monitoring & Record Linkage Systems
Similar to Drug utilization reviews
A PROSPECTIVE STUDY OF DRUG UTILIZATION PATTERN AND EVALUATION USING WHO GUI...
This document describes a prospective study conducted to evaluate drug utilization patterns and prescribing practices in a government hospital in India using WHO prescribing indicators. Data was collected from 282 patient records over 6 months across various wards. The study aimed to promote rational drug use, avoid polypharmacy, prevent antibiotic resistance, and estimate disease prevalence. Key metrics analyzed included the average number of drugs per prescription, percentage of generics prescribed, consultation times, and drug availability. The findings could provide insights into prescribing quality and opportunities for improvement.
Drug utilization review 1
This document discusses drug utilization review (DUR), which is a systematic process to ensure appropriate medication use. DUR involves reviewing patient medication and health histories before, during, and after dispensing. It can help prevent unnecessary drug use, adverse reactions, and improve effectiveness. The document outlines the classification, goals, and steps to establish a basic hospital DUR program, including forming a committee, developing policies/procedures, identifying drugs for review, establishing criteria, collecting/evaluating data, implementing interventions if needed, and re-evaluating the program annually.
Pharmaceutical care
The document discusses pharmaceutical care, which aims to achieve the best possible outcomes for patients' quality of life through proper medication use. It defines pharmaceutical care as the responsible provision of drug therapy to achieve definite therapeutic outcomes that improve a patient's quality of life. Key aspects of pharmaceutical care include identifying and resolving actual and potential drug-related problems through monitoring medication appropriateness, effectiveness, and safety. The roles of pharmacists include collecting patient data, assessing medications, developing individualized care plans, implementing and monitoring care to evaluate outcomes and modify plans as needed.
Drug utilization evaluation(DUE) & Drug utilization review)
Drug utilization evaluation (DUE) is a systematic, ongoing evaluation of drug therapy that ensures medications are used appropriately and meet current standards of care. The goals of DUE include promoting optimal medication therapy, creating guidelines for appropriate drug use, and controlling costs. The DUE process involves establishing responsibility, developing review criteria, collecting and analyzing data, providing feedback to prescribers, and conducting follow-up evaluations. Drug utilization review (DUR) similarly involves ongoing review of prescribing, dispensing, and drug use, and can be prospective, concurrent, or retrospective to identify problems and improve medication therapy.
ClinPhar-MODULE-2.pdf
Medication Therapy Management (MTM) involves pharmacists working with patients and other healthcare providers to optimize medication use, improve health outcomes, and reduce healthcare costs. Pharmacists provide MTM through activities like assessing patient health status, creating medication treatment plans, educating patients, and referring patients to disease management services. The goal is for pharmacists to help patients safely use medications to get the best benefits and prevent medication-related problems.
RDP-CP-PP.pdf
The document provides an overview of clinical pharmacy, including its definition, development, scope, and the functions and responsibilities of clinical pharmacists. It discusses key aspects of clinical pharmacy practice such as medication chart review, clinical review, pharmacist intervention, ward round participation, medication history, and pharmaceutical care. The summary is as follows:
Clinical pharmacy deals with the safe and effective use of drugs in patient care. It aims to optimize medication use and promote health. Clinical pharmacists are involved in medication monitoring, patient education, and ensuring rational drug therapy.
Key responsibilities of clinical pharmacists include collecting patient data, identifying drug-related problems, establishing treatment goals, evaluating and modifying drug regimens, and monitoring treatment outcomes.
In patient care
This document discusses several aspects of patient care including patient-centered care, inpatient care, services provided by an inpatient care department, the role of pharmacists in ensuring patient safety and quality care, and programs to promote appropriate medication use such as drug utilization review and prior authorization. It also describes how managed care pharmacists work to develop clinical programs, facilitate communication between patients and providers, design effective health benefit structures, and contract with various organizations to structure business arrangements that meet population needs.
“Intervention of a clinical pharmacist in order to reduce polypharmacy, avera...
“Intervention of a clinical pharmacist in order to reduce polypharmacy, average cost of therapy and percentage of patients received injections (parenterals) in pediatrics dept; study carried out at multi-specialty teaching hospital”
Drug Utilization Studies
This presentation describes the objectives, approach and application of Drug Utilization studies in Pharmacotherapeutics. This emphasizes on how to conduct a drug utilization studies.
Essential drug concept & Rational drug use.pptx
An Essential Drug List, also known as a core drug list or medication list, is a carefully selected inventory of medications that are deemed essential for addressing the most prevalent health conditions within a specific population or country. It serves as a key component of national drug policies and pharmaceutical programs, ensuring the availability, accessibility, and affordability of essential medicines. The list is typically developed based on rigorous criteria, taking into consideration the medications' safety, efficacy, cost-effectiveness, and suitability for primary healthcare settings.
Rational Drug Therapy refers to the systematic and evidence-based approach to prescribing medications, aiming to maximize therapeutic benefits while minimizing the risk of adverse effects. It involves following established therapeutic guidelines and clinical protocols to ensure that medications are prescribed in a manner that is appropriate for the patient's condition, taking into account factors such as age, weight, co-existing conditions, drug interactions, and individual response. Rational drug therapy promotes the use of medications based on sound scientific evidence, emphasizing the principles of efficacy, safety, and cost-effectiveness to optimize patient outcomes and improve overall healthcare quality.
clinical pharmacy .pptx
Clinical pharmacy is still developing in India. Clinical pharmacists work directly with patients, physicians, and other healthcare professionals to ensure safe and effective medication use. They collect patient medical histories, identify potential drug-related problems, establish treatment goals, evaluate treatment alternatives, monitor outcomes, and individualize drug regimens. In hospitals, clinical pharmacists are involved in prescription monitoring, advising medical staff, monitoring medication errors and adverse reactions, patient education, and participating in ward rounds.
Clinical pharmacy ppt
Introduction to Clinical Pharmacy, Concept of clinical pharmacy, functions and
responsibilities of clinical pharmacist, Drug therapy monitoring - medication chart
review, clinical review
DUR and DUE.ppt
Drug Utilization Review (DUR) and Drug Utilization Evaluation (DUE) are processes used to ensure appropriate and safe medication use. DUR involves ongoing review of prescribing, dispensing, and use of drugs, while DUE qualitatively evaluates drug therapy appropriateness. The objectives of DUR and DUE are to ensure drug therapy meets standards of care, improve quality and effectiveness, prevent adverse reactions, and encourage evidence-based use. Pharmacists play a key role by identifying opportunities for improvement and promoting appropriate drug use. A successful DUR/DUE program benefits members through improved outcomes and health plans through reduced costs.
Joint statement on appropriate um
This document discusses appropriate versus cost-driven approaches to utilization management of medications. It notes that cost-driven practices like prescription limits, therapeutic substitution, cost-sharing, and fail-first policies can negatively impact patients' health and increase overall costs. Alternatively, utilization management programs that promote high-value care through improved patient outcomes, like prescriber feedback, prescription case management, retrospective drug review, and value-based insurance design, can enhance quality of care while proving cost-effective. The summary concludes that for individuals with mental health conditions, appropriate pharmacy policies are important to support treatment and avoid risks to patient well-being.
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
b) Clinical Pharmacy
Introduction to Clinical Pharmacy, Concept of clinical pharmacy
Functions and responsibilities of clinical pharmacist, Drug therapy monitoring
Medication chart review, clinical review., pharmacist intervention
Ward round participation, Medication history and Pharmaceutical care.
Dosing pattern and drug therapy based on Pharmacokinetic & disease pattern
ASHP Standard for pharmacy supportive personnel
The document outlines 9 standards for pharmacy practice in hospitals established by the American Society of Health-System Pharmacy (ASHP). The standards address areas like practice management, medication policy development, optimizing medication therapy, drug procurement and inventory, medication preparation and labeling, dispensing and delivery, monitoring medication use, evaluating the medication system, and supporting research. The standards provide guidelines for minimum services pharmacy departments should provide, and encourage pharmacists to play a leadership role in collaborative medication management.
Good pharmacy practices.pptx
This document outlines the basic concepts of good pharmacy practice (GPP) according to standards developed by the International Pharmaceutical Federation in 1992. It discusses the six main components of pharmacy practice, which are being readily available to patients, identifying and managing health problems, health promotion, assuring medication effectiveness, preventing medication harm, and responsible resource use. The document then describes four main functions of pharmacists: preparing and handling medical products, providing medication therapy management, maintaining professional performance, and contributing to healthcare system and public health improvements.
An introduction to medication therapy management
Pharmacists: An Untapped Resource: Pharmacists receive more training on the safe, effective and appropriate use of medications than any other healthcare professional
Introduction Clinical Pharmacy Practices
Introduction to Clinical Pharmacy Practice, Definitions and Aim, Objectives, Scopes or services of Clinical Pharmacy, Functions and Roles of Clinical Pharmacy, Qualities of Clinical Pharmacy.
medication safety
The document discusses medication safety and outlines several key points:
1) The goal of the Iraqi Ministry of Health is to provide safe and effective medications to all patients through multidisciplinary teams including physicians, pharmacists, nurses and patients.
2) Medication safety involves appropriate prescribing, thorough risk-benefit analysis, and monitoring for adverse drug events, especially with polypharmacy which increases with age and multiple chronic conditions.
3) Education, training, protocols, supervision and communication are important strategies to reduce medication errors and ensure safe and effective use of medications.
Similar to Drug utilization reviews (20)
A PROSPECTIVE STUDY OF DRUG UTILIZATION PATTERN AND EVALUATION USING WHO GUI...
A PROSPECTIVE STUDY OF DRUG UTILIZATION PATTERN AND EVALUATION USING WHO GUI...
Drug utilization evaluation(DUE) & Drug utilization review)
Drug utilization evaluation(DUE) & Drug utilization review)
“Intervention of a clinical pharmacist in order to reduce polypharmacy, avera...
“Intervention of a clinical pharmacist in order to reduce polypharmacy, avera...
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
Clinical Pharmacy Introduction to Clinical Pharmacy, Concept of clinical pptx
More from Shri guru ram rai institute of technology and science
Drugs used in constipation & diarrhoea
Constipation is a comdition which causes difficulty in ecretion of feaces, less than three bowel in a week. the drugs that are used to treat constipation are cathartics.
Diarrhoea is a condition of excretion of loose stool and water equal or more than three bowel movement in a day. it is of three types, acute, dysentry, chronic diarrrhoea. may caused by bacteria E.coli, and Rotavirus in children. drugs used to treat are called anti diarrhoeal drugs.
Fecal tests or stool tests
Fecal or stool tests examine human feces to check for various indicators of health conditions. Feces should be collected in a clean, dry container without contamination from urine or other substances. Macroscopic examination of feces considers characteristics like color, odor, blood, mucus, and consistency. Tests on feces can check for blood, which may indicate issues in the upper intestinal tract, and fats, to detect malabsorption. Parasite examination looks for worms or their eggs. Liver function tests evaluate enzymes and proteins that provide information about hepatic function by examining levels in urine and stool. Radioiodine uptake tests also use stool samples to check thyroid function.
International drug regulatory affairs
The document discusses international drug regulatory affairs. It provides an overview of the regulatory structures and agencies that govern the pharmaceutical industry. The key regulatory bodies discussed include the FDA in the US, EMEA in Europe, and other agencies in countries like Japan, Australia, Brazil, Nigeria, China, and India. The document also summarizes the various approval processes for new drugs and generics, including requirements for clinical trials, applications, and common technical dossier formats. Common challenges in international regulatory approval are also briefly mentioned.
DVT by shipra omar
Rudolf Virchow identified three main factors that contribute to thromboembolism: venous stasis, hypercoagulability, and endothelial injury. Deep vein thrombosis is the formation of a blood clot in the deep veins, usually in the legs. Signs and symptoms include pain, swelling, redness, and tenderness. Diagnosis involves physical exam, D-dimer test, ultrasound, CT scan, and pulmonary angiogram. Treatment consists of anticoagulants like heparin and warfarin to prevent clot extension and recurrence, as well as thrombolytics, surgery, and IVC filters in some cases.
Teratogenecity
a detailed description of drugs on the pregnant mothers and foetus.
in this presentation, the Catagories are defined for various drugs.
Cardio toxicity
Cardiotoxicity refers to heart damage caused by certain chemotherapy drugs, heavy metals, and other toxins. Three main mechanisms of cardiotoxicity are discussed: interfering with aerobic metabolism in the heart, altering myocardial conduction, and directly damaging heart muscle cells. Symptoms of cardiotoxicity include fatigue, shortness of breath, and swelling. Diagnosis involves physical exams, imaging tests like echocardiograms and MUGA scans, and blood tests. Prevention strategies center around modifying drug treatment plans, using protective medications like dexrazoxane, and controlling risk factors after treatment through medications like ACE inhibitors and beta-blockers.
More from Shri guru ram rai institute of technology and science (6)
Recently uploaded
Efficacy of Avartana Sneha in Ayurveda
Avartana Sneha is a unique method of Preparation of Sneha Kalpana in Ayurveda, mainly it is indicated for the Vataja rogas.
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Overall life span (LS) was 1671.7±1721.6 days and cumulative 5YS reached 62.4%, 10 years – 50.4%, 20 years – 44.6%. 94 LCP lived more than 5 years without cancer (LS=2958.6±1723.6 days), 22 – more than 10 years (LS=5571±1841.8 days). 67 LCP died because of LC (LS=471.9±344 days). AT significantly improved 5YS (68% vs. 53.7%) (P=0.028 by log-rank test). Cox modeling displayed that 5YS of LCP significantly depended on: N0-N12, T3-4, blood cell circuit, cell ratio factors (ratio between cancer cells-CC and blood cells subpopulations), LC cell dynamics, recalcification time, heparin tolerance, prothrombin index, protein, AT, procedure type (P=0.000-0.031). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and N0-12 (rank=1), thrombocytes/CC (rank=2), segmented neutrophils/CC (3), eosinophils/CC (4), erythrocytes/CC (5), healthy cells/CC (6), lymphocytes/CC (7), stick neutrophils/CC (8), leucocytes/CC (9), monocytes/CC (10). Correct prediction of 5YS was 100% by neural networks computing (error=0.000; area under ROC curve=1.0).
Identifying Major Symptoms of Slip Disc.
Our backs are like superheroes, holding us up and helping us move around. But sometimes, even superheroes can get hurt. That’s where slip discs come in.
share - Lions, tigers, AI and health misinformation, oh my!.pptx
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
All info about Diabetes and how to control it.
One health condition that is becoming more common day by day is diabetes.
According to research conducted by the National Family Health Survey of India, diabetic cases show a projection which might increase to 10.4% by 2030.
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
It includes regulation of combination products and medical devices. FDA and industry liaisons.
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS). Parc Taulí. Sabadell
Hiranandani Hospital Powai News [Read Now].pdf
Hiranandani Hospital in Powai, Mumbai, is a premier healthcare institution that has been serving the community with exceptional medical care since its establishment. As a part of the renowned Hiranandani Group, the hospital is committed to delivering world-class healthcare services across a wide range of specialties, including kidney transplantation. With its state-of-the-art facilities, advanced medical technology, and a team of highly skilled healthcare professionals, Hiranandani Hospital has earned a reputation as a trusted name in the healthcare industry. The hospital's patient-centric approach, coupled with its focus on innovation and excellence, ensures that patients receive the highest standard of care in a compassionate and supportive environment.
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
Histololgy of Female Reproductive System.pptx
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Recently uploaded (20)
Tests for analysis of different pharmaceutical.pptx
Tests for analysis of different pharmaceutical.pptx
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
CHEMOTHERAPY_RDP_CHAPTER 6_Anti Malarial Drugs.pdf
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
Local Advanced Lung Cancer: Artificial Intelligence, Synergetics, Complex Sys...
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
REGULATION FOR COMBINATION PRODUCTS AND MEDICAL DEVICES.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotes
Drug utilization reviews
- 1. DRUG UTILIZATION EVALUATIONDRUG UTILIZATION EVALUATION && DRUG UTILIZATION REVIEWDRUG UTILIZATION REVIEW Presented by:- Nirmal singh parihar Shipra omar Gaurav kant gupta Presented to:- MR. Prashant kr. Katiyar(HOD) Miss priyadarshini agrawal (Assistant professor) KIT Kanpur
- 2. INTRODUCTION:-INTRODUCTION:- Drug Utilization Reviews (DUR), also referred to as Drug Utilization Evaluations (DUE) or Medication utilization Evaluations (MUE), are defined as an authorized, structured, ongoing review of healthcare provider prescribing, pharmacist dispensing, and patient use of medication. DURs involve comprehensive review of patients' prescription and medication data before, during, and after dispensing to ensure appropriate medication decision making and positive patient outcomes. Along with MUE DUE and DUR , it came in year 1969
- 3. PROSPECTIVES:-PROSPECTIVES:- Promoting optimal medication therapy. Preventing medication-related problems. Evaluating the effectiveness of medication therapy. Improving patient safety. Establishing interdisciplinary consensus on medication- use processes. Stimulating improvements in medication-use processes. Stimulating standardization in medication-use processes
- 4. Issues Commonly Addressed byIssues Commonly Addressed by Prospective DUR:Prospective DUR: Therapeutic interchange Drug-disease contraindications Generic substitution Incorrect drug dosage Clinical abuse/misuse Inappropriate duration of drug treatment Drug-allergy interactions
- 5. Why DURs are important:Why DURs are important: DUR programs play a key role in helping managed health care systems understand, interpret improve the prescribing, administration, and use of medications. Employers and health plans find DUR programs valuable because the results are used to foster more efficient use of scarce health care resources. Pharmacists play a key role in this process because of their expertise in the area of pharmaceutical care.
- 6. DRUG UTILIZATION PROCESS:-DRUG UTILIZATION PROCESS:-
- 7. VALUE OF DRU PROGRAMS:-VALUE OF DRU PROGRAMS:- DUR information also allows for the compare and contrasting of healthcare providers in order to evaluate a particular provider's approach to treating certain diseases against their peers. These comparisons are useful in stimulating physicians to change their prescribing habits in an effort to improve care.
- 8. Contd…..Contd….. DUR information also assists managed health care systems and managers in designing educational programs that improve rational prescribing, formulary compliance, and patient compliance. These educational programs may take the form of face-to-face education of physicians and patients by clinical pharmacists, telephone calls, letters, newsletters, and educational symposia.
- 9. TYPES OF DRU:-TYPES OF DRU:- Prospective - evaluation of a patient's therapy before medication is dispensed • Concurrent - ongoing monitoring of drug therapy during the course of treatment • Retrospective - review of therapy after the patient has received the medication